Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egeberg

Showing results (291-300 of 332) with videos related to

Pageof 34
Sort By:
Journal of the American Academy of Dermatology|November 30, 2020
Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysisNina H Ravn, Zohra F Ahmadzay, Tine A Christensen, et al.
The Journal of Rheumatology|July 17, 2019
Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry StudyMarie Skougaard, Tanja Schjødt Jørgensen, Signe Rifbjerg-Madsen, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
The British Journal of Dermatology|November 9, 2025
Patient preferences for treatment of atopic dermatitis: findings from the Danish Skin CohortSascha D W Stave, Lea K Nymand, Silvia M Ferrucci, et al.
Journal of Comparative Effectiveness Research|February 28, 2023
A plain language summary of what freedom from disease means to people with psoriasis according to doctors, nurses, and people with psoriasisIlse van Ee, Elfie Deprez, Alexander Egeberg, et al.
The Lancet Regional Health. Europe|July 19, 2023
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)Mette Gyldenløve, Howraman Meteran, Jennifer A Sørensen, et al.
American Journal of Clinical Dermatology|October 13, 2021
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
American Journal of Clinical Dermatology|August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 10, 2025
Temporal Trends in the Course and Management of Chronic Urticaria at a European Tertiary CenterClara Emilie Syrene Østergaard, Mette Iversen, Nadja Højgaard Pedersen, et al.
Pageof 34

Showing results (291-300 of 332) with videos related to

Sort By:
Pageof 34
Journal of the American Academy of Dermatology|November 30, 2020
Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysisNina H Ravn, Zohra F Ahmadzay, Tine A Christensen, et al.
The Journal of Rheumatology|July 17, 2019
Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry StudyMarie Skougaard, Tanja Schjødt Jørgensen, Signe Rifbjerg-Madsen, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
The British Journal of Dermatology|November 9, 2025
Patient preferences for treatment of atopic dermatitis: findings from the Danish Skin CohortSascha D W Stave, Lea K Nymand, Silvia M Ferrucci, et al.
Journal of Comparative Effectiveness Research|February 28, 2023
A plain language summary of what freedom from disease means to people with psoriasis according to doctors, nurses, and people with psoriasisIlse van Ee, Elfie Deprez, Alexander Egeberg, et al.
The Lancet Regional Health. Europe|July 19, 2023
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)Mette Gyldenløve, Howraman Meteran, Jennifer A Sørensen, et al.
American Journal of Clinical Dermatology|October 13, 2021
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
American Journal of Clinical Dermatology|August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 10, 2025
Temporal Trends in the Course and Management of Chronic Urticaria at a European Tertiary CenterClara Emilie Syrene Østergaard, Mette Iversen, Nadja Højgaard Pedersen, et al.
Pageof 34